Cargando…

Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathways

BACKGROUND: To determine the protein expression profile (PEP) of primary and recurrent ovarian cancer patients in order to predict therapeutic targets for chemotherapy. METHODS: Tissue samples were submitted for PEP in two formats, including formalin-fixed paraffin-embedded tissue for immunohistoche...

Descripción completa

Detalles Bibliográficos
Autores principales: Foss, Cassandra D, Dalton, Heather J, Monk, Bradley J, Chase, Dana M, Farley, John H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877732/
https://www.ncbi.nlm.nih.gov/pubmed/27231557
http://dx.doi.org/10.1186/2053-6844-1-4
_version_ 1782433433440485376
author Foss, Cassandra D
Dalton, Heather J
Monk, Bradley J
Chase, Dana M
Farley, John H
author_facet Foss, Cassandra D
Dalton, Heather J
Monk, Bradley J
Chase, Dana M
Farley, John H
author_sort Foss, Cassandra D
collection PubMed
description BACKGROUND: To determine the protein expression profile (PEP) of primary and recurrent ovarian cancer patients in order to predict therapeutic targets for chemotherapy. METHODS: Tissue samples were submitted for PEP in two formats, including formalin-fixed paraffin-embedded tissue for immunohistochemistry (IHC) and fresh frozen tissue for oligonucleotide microarray (MA) gene expression assays. Specimens were analyzed for 18 protein markers and 88 MA genes. A series of Generalized Linear Models (GLM) was used to predict the proportion of positive results by histology for each biomarker. RESULTS: Four hundred and twenty-eight specimens were analyzed for IHC and 67 specimens for MA analysis. The majority of specimens, 82%, were serous histology and 35.3% of specimens were poorly differentiated. Sixty percent of specimens were advanced stage, 62% were from a primary diagnosis, and 53% were obtained from a metastatic site. BCRP, ER, MGMT, and RRM1 proteins were overexpressed in 85%, 47%, 93%, and 47% of serous carcinomas, respectively. The MGMT and RRM1 biomarkers were significantly overexpressed in serous (p < .001) and endometrioid (p = .01) histologies when compared to clear cell histology. MGMT was significantly elevated in 93% of serous and endometrioid samples, compared to 62% of samples with clear cell histology. Those proteins most often underexpressed included Her2/neu, SPARC, and c-kit, seen in less than 1%, 4%, and 5% of specimens, respectively. CONCLUSIONS: PEP is a reliable and effective way of analyzing ovarian cancer specimens. PEP target identification does not appear to vary significantly with site evaluated, ovarian or other abdominal pelvic tissue, or primary versus recurrent disease. Variability in the expression of drug targets, including BCRP, ER, MGMT, and RRM1 could impact decision making pertaining to which therapeutic strategies carry the best chances for controlling disease. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/2053-6844-1-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4877732
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48777322016-05-26 Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathways Foss, Cassandra D Dalton, Heather J Monk, Bradley J Chase, Dana M Farley, John H Gynecol Oncol Res Pract Research BACKGROUND: To determine the protein expression profile (PEP) of primary and recurrent ovarian cancer patients in order to predict therapeutic targets for chemotherapy. METHODS: Tissue samples were submitted for PEP in two formats, including formalin-fixed paraffin-embedded tissue for immunohistochemistry (IHC) and fresh frozen tissue for oligonucleotide microarray (MA) gene expression assays. Specimens were analyzed for 18 protein markers and 88 MA genes. A series of Generalized Linear Models (GLM) was used to predict the proportion of positive results by histology for each biomarker. RESULTS: Four hundred and twenty-eight specimens were analyzed for IHC and 67 specimens for MA analysis. The majority of specimens, 82%, were serous histology and 35.3% of specimens were poorly differentiated. Sixty percent of specimens were advanced stage, 62% were from a primary diagnosis, and 53% were obtained from a metastatic site. BCRP, ER, MGMT, and RRM1 proteins were overexpressed in 85%, 47%, 93%, and 47% of serous carcinomas, respectively. The MGMT and RRM1 biomarkers were significantly overexpressed in serous (p < .001) and endometrioid (p = .01) histologies when compared to clear cell histology. MGMT was significantly elevated in 93% of serous and endometrioid samples, compared to 62% of samples with clear cell histology. Those proteins most often underexpressed included Her2/neu, SPARC, and c-kit, seen in less than 1%, 4%, and 5% of specimens, respectively. CONCLUSIONS: PEP is a reliable and effective way of analyzing ovarian cancer specimens. PEP target identification does not appear to vary significantly with site evaluated, ovarian or other abdominal pelvic tissue, or primary versus recurrent disease. Variability in the expression of drug targets, including BCRP, ER, MGMT, and RRM1 could impact decision making pertaining to which therapeutic strategies carry the best chances for controlling disease. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/2053-6844-1-4) contains supplementary material, which is available to authorized users. BioMed Central 2014-09-30 /pmc/articles/PMC4877732/ /pubmed/27231557 http://dx.doi.org/10.1186/2053-6844-1-4 Text en © Foss et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Foss, Cassandra D
Dalton, Heather J
Monk, Bradley J
Chase, Dana M
Farley, John H
Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathways
title Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathways
title_full Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathways
title_fullStr Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathways
title_full_unstemmed Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathways
title_short Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathways
title_sort protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathways
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4877732/
https://www.ncbi.nlm.nih.gov/pubmed/27231557
http://dx.doi.org/10.1186/2053-6844-1-4
work_keys_str_mv AT fosscassandrad proteinprofilingofovariancancersbyimmunohistochemistrytoidentifypotentialtargetpathways
AT daltonheatherj proteinprofilingofovariancancersbyimmunohistochemistrytoidentifypotentialtargetpathways
AT monkbradleyj proteinprofilingofovariancancersbyimmunohistochemistrytoidentifypotentialtargetpathways
AT chasedanam proteinprofilingofovariancancersbyimmunohistochemistrytoidentifypotentialtargetpathways
AT farleyjohnh proteinprofilingofovariancancersbyimmunohistochemistrytoidentifypotentialtargetpathways